Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-03-18 9:13 pm Purchase | 13D | REGULUS THERAPEUTICS INC RGLS | Growth Equity Opportunities V LLC | 6,533,102 9.99% | 4,587,523 (+235.79%) | View |
| 2023-05-12 1:57 pm Sale | 13D | REGULUS THERAPEUTICS INC RGLS | Growth Equity Opportunities V LLC | 1,945,579 9.99% | -12,636,942 (-86.66%) | View |
| 2023-03-09 4:10 pm Sale | 13D | MEI PHARMA INC MEIP | Growth Equity Opportunities V LLC | 0 0% | -9,963,216 (Position Closed) | View |
| 2022-07-22 4:06 pm Sale | 13D | CTI BIOPHARMA CORP CTIC | Growth Equity Opportunities V LLC | 0 0% | -9,613,101 (Position Closed) | View |
| 2022-06-17 5:10 pm Purchase | 13D | CTI BIOPHARMA CORP CTIC | Growth Equity Opportunities V LLC | 9,613,101 8.8% | 2,228,285 (+30.17%) | View |
| 2021-12-09 2:58 pm Purchase | 13D | REGULUS THERAPEUTICS INC RGLS | Growth Equity Opportunities V LLC | 14,582,521 9.99% | 12,530,067 (+610.49%) | View |
| 2021-11-19 06:44 am Sale | 13D | Trillium Therapeutics Inc. TRIL | Growth Equity Opportunities V LLC | 0 0% | -6,586,363 (Position Closed) | View |
| 2021-08-31 6:43 pm Unchanged | 13D | Trillium Therapeutics Inc. TRIL | Growth Equity Opportunities V LLC | 6,586,363 6.3% | 0 (Unchanged) | View |
| 2020-03-12 08:03 am Purchase | 13D | CTI BIOPHARMA CORP CTIC | Growth Equity Opportunities V LLC | 7,384,816 9.99% | 3,634,816 (+96.93%) | View |
| 2020-02-13 10:46 am Unchanged | 13D | CTI BIOPHARMA CORP CTIC | Growth Equity Opportunities V LLC | 3,750,000 6.5% | 0 (Unchanged) | View |
| 2020-02-04 5:19 pm Purchase | 13D | Trillium Therapeutics Inc. TRIL | Growth Equity Opportunities V LLC | 6,586,363 8.7% | 4,462,453 (+210.11%) | View |
| 2019-12-30 3:47 pm Purchase | 13D | MEI PHARMA INC MEIP | Growth Equity Opportunities V LLC | 9,963,216 9.8% | 2,937,575 (+41.81%) | View |
| 2019-05-15 2:35 pm Sale | 13D | REGULUS THERAPEUTICS INC RGLS | Growth Equity Opportunities V LLC | 2,052,454 9.99% | -8,936,556 (-81.32%) | View |